London: In a new study, scientists have discovered a molecule that can “regrow” damaged cartilage, which has offered hope to millions of people crippled by arthritis.
The finding could be the breakthrough experts need to create a drug capable of halting and then reversing the degenerative joint disease.
Osteoarthritis, the most common form of the condition, blights the lives of 8.5 million people in Britain. It is caused by wear and tear of joints where the cartilage that cushions movement is eaten away.
Bones then come into contact with each other and the friction makes joints swollen and extremely painful, leaving many sufferers in agony.
Current treatments can only relieve the painful symptoms of the disease. One drug was recently approved for use in Britain, which can dramatically slow its progress but it is still incurable and often leads to costly knee replacements.
Now researchers at the Scripps Institute in California and the Genomics Institute of the Novartis Research Foundation in San Diego have found a molecule called kartogenin, which spurs cartilage regeneration in mice.
According to the researchers, their findings suggest that the molecule could be the basis of a new drug-based therapy for osteoarthritis.
Although more research is needed, it is likely it would be administered by an injection straight to the damaged area.
Kristen Johnson and colleagues discovered that kartogenin works by coaxing stem cells to change into cartilage cells.
When administered to mice with osteoarthritis-like symptoms, kartogenin triggered cartilage development.
The molecule works by disrupting the interaction between two proteins, taking control of a family of proteins that play a key role in musculoskeletal development.
“This may ultimately lead to a stem-cell based therapy for osteoarthritis,” the Daily Express quoted the authors of the study as saying.
At present many sufferers have to rely on anti-inflammatory painkillers, though these can damage the stomach when used long-term. In severe cases, joints are replaced. The NHS carries out more than 140,000 hip and knee replacements each year at a cost of more than 1 billion pounds.
Some patients have to undergo two operations because artificial hips or knees can wear out after 15 years. A new drug treatment for osteoarthritis would therefore save the NHS a fortune.
“We`ve known for some time that adult stem cells have the potential to develop into cartilage cells and this research supports this idea. The real challenge now is to turn these initial findings into treatment for patients,” Alan Silman, medical director of Arthritis Research UK, said.
“Researchers at Arthritis Research UK`s tissue engineering centre are exploring how adult stem cells can be used to develop an injectable treatment to reduce the pain and disability caused by osteoarthritis,” Silman added.
The study has been published online in the journal Science.
ANI
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookies Setting
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device and the processing of information obtained via those cookies (including about your preferences, device and online activity) by us and our commercial partners to enhance site navigation, personalise ads, analyze site usage, and assist in our marketing efforts. More information can be found in our Cookies and Privacy Policy. You can amend your cookie settings to reject non-essential cookies by clicking Cookie Settings below.
Manage Consent Preferences
Strictly Necessary Cookies
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work or you may not be able to login.
Functional Cookies
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They are also used to limit the number of times you see an advert as well as help measure the effectiveness of an advertising campaign. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we may not know when you have visited our site, and may not be able to monitor its performance.